Published in Trends Endocrinol Metab on October 17, 2008
Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology (2009) 4.82
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 2.92
Adipocyte apoptosis, a link between obesity, insulin resistance, and hepatic steatosis. J Biol Chem (2009) 2.11
Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression. Hepatology (2015) 1.81
Hepatic insulin resistance in mice with hepatic overexpression of diacylglycerol acyltransferase 2. Proc Natl Acad Sci U S A (2011) 1.55
Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World J Gastroenterol (2011) 1.52
Resolvins, specialized proresolving lipid mediators, and their potential roles in metabolic diseases. Cell Metab (2013) 1.45
Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21
Absence of adipose differentiation related protein upregulates hepatic VLDL secretion, relieves hepatosteatosis, and improves whole body insulin resistance in leptin-deficient mice. J Lipid Res (2010) 1.19
Genetic variation at NCAN locus is associated with inflammation and fibrosis in non-alcoholic fatty liver disease in morbid obesity. Hum Hered (2013) 1.17
A negative regulatory pathway of GLUT4 trafficking in adipocyte: new function of RIP140 in the cytoplasm via AS160. Cell Metab (2009) 1.16
Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol (2010) 1.14
PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease. PPAR Res (2010) 1.11
Ethnic differences in pancreatic fat accumulation and its relationship with other fat depots and inflammatory markers. Diabetes Care (2011) 1.09
Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat Rev Gastroenterol Hepatol (2012) 1.07
Nonalcoholic fatty liver disease and aging: epidemiology to management. World J Gastroenterol (2014) 1.05
Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. Biofactors (2010) 1.04
Pediatric non-alcoholic fatty liver disease: preventive and therapeutic value of lifestyle intervention. World J Gastroenterol (2009) 1.01
High-fat diet induced obesity primes inflammation in adipose tissue prior to liver in C57BL/6j mice. Aging (Albany NY) (2015) 1.01
PTEN in liver diseases and cancer. World J Gastroenterol (2010) 0.97
FOXO1 increases CCL20 to promote NF-κB-dependent lymphocyte chemotaxis. Mol Endocrinol (2012) 0.96
New insights into the role of macrophages in adipose tissue inflammation and Fatty liver disease: modulation by endogenous omega-3 Fatty Acid-derived lipid mediators. Front Immunol (2011) 0.93
Triangulated mal-signaling in Alzheimer's disease: roles of neurotoxic ceramides, ER stress, and insulin resistance reviewed. J Alzheimers Dis (2012) 0.91
Upstream transcription factor 1 influences plasma lipid and metabolic traits in mice. Hum Mol Genet (2009) 0.91
Intrauterine growth retardation and nonalcoholic Fatty liver disease in children. Int J Endocrinol (2011) 0.90
Adipocyte hypertrophy is associated with lysosomal permeability both in vivo and in vitro: role in adipose tissue inflammation. Am J Physiol Endocrinol Metab (2012) 0.89
Ameliorative effect of myricetin on insulin resistance in mice fed a high-fat, high-sucrose diet. Nutr Res Pract (2014) 0.88
Inhibition of HMGB1 release via salvianolic acid B-mediated SIRT1 up-regulation protects rats against non-alcoholic fatty liver disease. Sci Rep (2015) 0.88
Nuclear receptors reverse McGarry's vicious cycle to insulin resistance. Cell Metab (2012) 0.87
Hypoxia and fatty liver. World J Gastroenterol (2014) 0.86
Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Front Cell Infect Microbiol (2012) 0.85
Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines. Medicine (Baltimore) (2016) 0.85
Cytokeratin-18 fragments and biomarkers of the metabolic syndrome in nonalcoholic steatohepatitis. World J Gastroenterol (2009) 0.84
The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice. PLoS One (2016) 0.83
A cell-type-specific role for murine Commd1 in liver inflammation. Biochim Biophys Acta (2014) 0.83
Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease. World J Gastroenterol (2013) 0.83
Hepatic function and the cardiometabolic syndrome. Diabetes Metab Syndr Obes (2013) 0.83
Microparticles release by adipocytes act as "find-me" signals to promote macrophage migration. PLoS One (2015) 0.83
Nonalcoholic fatty liver disease and the heart in children and adolescents. World J Gastroenterol (2014) 0.83
Prediction of metabolic syndrome by non-alcoholic fatty liver disease in northern urban Han Chinese population: a prospective cohort study. PLoS One (2014) 0.82
Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis activates Akt signaling to ameliorate hepatic steatosis. Sci Rep (2016) 0.82
Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. Clin Pharmacol Ther (2010) 0.81
Tumor necrosis factor α-converting enzyme inhibition reverses hepatic steatosis and improves insulin sensitivity markers and surgical outcome in mice. PLoS One (2011) 0.81
Dietary sugars: a fat difference. J Clin Invest (2009) 0.81
Deficiency of oncostatin M receptor β (OSMRβ) exacerbates high-fat diet-induced obesity and related metabolic disorders in mice. J Biol Chem (2014) 0.81
Hepatocyte TRAF3 promotes liver steatosis and systemic insulin resistance through targeting TAK1-dependent signalling. Nat Commun (2016) 0.81
Insights into the Role and Interdependence of Oxidative Stress and Inflammation in Liver Diseases. Oxid Med Cell Longev (2016) 0.80
Gut Microbiota and Lifestyle Interventions in NAFLD. Int J Mol Sci (2016) 0.79
Apocynin improves insulin resistance through suppressing inflammation in high-fat diet-induced obese mice. Mediators Inflamm (2011) 0.79
Hyperinsulinemia shifted energy supply from glucose to ketone bodies in early nonalcoholic steatohepatitis from high-fat high-sucrose diet induced Bama minipigs. Sci Rep (2015) 0.79
The association of circulating levels of complement-C1q TNF-related protein 5 (CTRP5) with nonalcoholic fatty liver disease and type 2 diabetes: a case-control study. Diabetol Metab Syndr (2015) 0.79
Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol (2016) 0.79
Reduction of obesity-associated white adipose tissue inflammation by rosiglitazone is associated with reduced non-alcoholic fatty liver disease in LDLr-deficient mice. Sci Rep (2016) 0.78
The novel association between red complex of oral microbe and body mass index in healthy Japanese: a population based cross-sectional study. J Clin Biochem Nutr (2015) 0.78
Animal models of insulin resistance and heart failure. Heart Fail Rev (2014) 0.78
Lysosomal Cathepsin D contributes to cell death during adipocyte hypertrophy. Adipocyte (2013) 0.78
Nonalcoholic fatty liver disease as a multi-systemic disease. World J Gastroenterol (2016) 0.78
Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis. PLoS One (2015) 0.78
Glycolipid Metabolism Disorder in the Liver of Obese Mice Is Improved by TUDCA via the Restoration of Defective Hepatic Autophagy. Int J Endocrinol (2015) 0.78
Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. Int J Mol Sci (2014) 0.78
Hematopoietic tissue factor-protease-activated receptor 2 signaling promotes hepatic inflammation and contributes to pathways of gluconeogenesis and steatosis in obese mice. Am J Pathol (2014) 0.78
Xylobiose, an Alternative Sweetener, Ameliorates Diabetes-Related Metabolic Changes by Regulating Hepatic Lipogenesis and miR-122a/33a in db/db Mice. Nutrients (2016) 0.78
The AST/ALT (De-Ritis) ratio: A novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. Medicine (Baltimore) (2016) 0.77
FOXO1 involvement in insulin resistance-related pro-inflammatory cytokine production in hepatocytes. Inflamm Res (2012) 0.77
Metabolic derangements mediate cognitive impairment and Alzheimer's disease: role of peripheral insulin-resistance diseases. Panminerva Med (2012) 0.77
The Crosstalk between Hypoxia and Innate Immunity in the Development of Obesity-Related Nonalcoholic Fatty Liver Disease. Biomed Res Int (2015) 0.76
Increased expression of triggering receptor expressed on myeloid cells-1 in the population with obesity and insulin resistance. Obesity (Silver Spring) (2017) 0.76
Reprogramming of hepatic fat accumulation and 'browning' of adipose tissue by the short-chain fatty acid acetate. Int J Obes (Lond) (2016) 0.76
Anti-Inflammatory Effects of Spirulina platensis Extract via the Modulation of Histone Deacetylases. Nutrients (2016) 0.76
Downhill Running-Based Overtraining Protocol Improves Hepatic Insulin Signaling Pathway without Concomitant Decrease of Inflammatory Proteins. PLoS One (2015) 0.75
Increased risk of nonalcoholic fatty liver disease with occupational stress in Chinese policemen: A 4-year cohort study. Medicine (Baltimore) (2016) 0.75
Cordyceps militaris alleviates non-alcoholic fatty liver disease in ob/ob mice. Nutr Res Pract (2014) 0.75
Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms. Aliment Pharmacol Ther (2016) 0.75
Associations between White Blood Cell Count and the Development of Incidental Nonalcoholic Fatty Liver Disease. Gastroenterol Res Pract (2016) 0.75
Inhibition of MEK1 Signaling Pathway in the Liver Ameliorates Insulin Resistance. J Diabetes Res (2015) 0.75
Glycine N-methyltransferase deficiency in female mice impairs insulin signaling and promotes gluconeogenesis by modulating the PI3K/Akt pathway in the liver. J Biomed Sci (2016) 0.75
C-reactive protein does not impair insulin suppression of glucose release in primary hepatocytes. Nutr Metab Cardiovasc Dis (2010) 0.75
Hyper- and hypo- nutrition studies of the hepatic transcriptome and epigenome suggest that PPARα regulates anaerobic glycolysis. Sci Rep (2017) 0.75
Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease. Sci Rep (2017) 0.75
Pediatric Non-Alcoholic Fatty Liver Disease. Children (Basel) (2017) 0.75
The impact of cereal grain consumption on the development and severity of non-alcoholic fatty liver disease. Eur J Nutr (2014) 0.75
The Association between Pediatric NAFLD and Common Genetic Variants. Children (Basel) (2017) 0.75
Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol (2006) 10.05
Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology (2010) 4.76
Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology (2007) 3.18
Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus. Nat Med (2013) 2.93
Inflammatory mechanisms in the regulation of insulin resistance. Mol Med (2008) 2.71
Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-κB-inducible immune pathways. Immunity (2011) 2.20
Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) (2008) 1.52
Increased expression of CCL20 in human inflammatory bowel disease. J Clin Immunol (2004) 1.50
Obesity and the microbiota. Gastroenterology (2009) 1.49
The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Cell Metab (2014) 1.47
Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin Immunol (2004) 1.26
Inflammation, cytokines and insulin resistance: a clinical perspective. Arch Immunol Ther Exp (Warsz) (2013) 1.08
Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice. J Hepatol (2005) 1.07
Adiponectin and its receptors in patients with chronic hepatitis C. J Hepatol (2005) 1.04
How to modulate inflammatory cytokines in liver diseases. Liver Int (2006) 1.02
Pathways of liver injury in alcoholic liver disease. J Hepatol (2011) 0.97
Visceral adipose tissue attacks beyond the liver: esophagogastric junction as a new target. Gastroenterology (2010) 0.95
Metabolic inflammation: role of cytokines in the crosstalk between adipose tissue and liver. Can J Physiol Pharmacol (2013) 0.86
The role of lipocalin-2 in liver regeneration. Liver Int (2014) 0.84
IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation. J Hepatol (2011) 0.84
Evolving therapies for non-alcoholic steatohepatitis. Expert Opin Drug Discov (2014) 0.82
Adipocytokines and hepatocellular carcinoma. Dig Dis (2012) 0.81
Suppression of interleukin-17 by type I interferons: a contributing factor in virus-induced immunosuppression? Eur Cytokine Netw (2009) 0.81
Heterogeneity of fibrosis patterns in non-alcoholic fatty liver disease supports the presence of multiple fibrogenic pathways. Liver Int (2013) 0.78
Malnutrition and microbiota--a new relationship? Nat Rev Gastroenterol Hepatol (2013) 0.77
Proinflammatory wheat attacks on the intestine: alpha-amylase trypsin inhibitors as new players. Gastroenterology (2013) 0.76
Corrigendum: IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun (2015) 0.75
Relevance of TNF-α gene polymorphisms in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol (2011) 0.75